Cite
Palbociclib in Patients With Pancreatic and Biliary Cancer With
MLA
Tareq, Al Baghdadi, et al. “Palbociclib in Patients With Pancreatic and Biliary Cancer With.” JCO Precision Oncology, vol. 3, Feb. 2022. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.pmid..........86aa7d4bc815620e8bf359db38695fd6&authtype=sso&custid=ns315887.
APA
Tareq, A. B., Susan, H., Elizabeth, G.-M., Pam K, M., Eugene R, A., Vaibhav, S., Ricardo H, A., Edward S, K., Kathleen J, Y., Andrew Lawrence, R., Kaitlyn R, A., Nicole L, B., Suanna S, B., & Richard L, S. (2022). Palbociclib in Patients With Pancreatic and Biliary Cancer With. JCO Precision Oncology, 3.
Chicago
Tareq, Al Baghdadi, Halabi Susan, Garrett-Mayer Elizabeth, Mangat Pam K, Ahn Eugene R, Sahai Vaibhav, Alvarez Ricardo H, et al. 2022. “Palbociclib in Patients With Pancreatic and Biliary Cancer With.” JCO Precision Oncology 3 (February). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.pmid..........86aa7d4bc815620e8bf359db38695fd6&authtype=sso&custid=ns315887.